%0 Journal Article
%T 减瘤性前列腺根治术临床预后分析<br>Clinical Prognosis Analysis of Cytoreductive Radical Prostatectomy
%A 冷康
%J Advances in Clinical Medicine
%P 3542-3549
%@ 2161-8720
%D 2023
%I Hans Publishing
%R 10.12677/ACM.2023.133507
%X 目前转移性前列腺癌(Metastatic prostate cancer, mPCa)患者标准治疗方式为内分泌治疗，此类患者临床预后较差，已有研究证明mPCa患者行减瘤性前列腺根治术(cytoreductive radical prostatectomy, CRP)可以延长患者生存期、减少并发症等，但对于此手术的可靠性及价值仍有待商榷。在我国，部分PCa患者确诊时已进入远处转移阶段，本文综合国内外研究对转移性前列腺癌患者行减瘤性手术的临床预后进行初步探讨。<br />
Currently, the standard treatment for a patient with metastatic prostate cancer (mPCa) is endocrine therapy. In this case, the clinical prognosis is poor. It has been proved that cytoreductive radical prostatectomy (CRP) can prolong survival and reduce complications in mPCa patients, but the reliability and value of this surgery remain to be discussed. In our country, some PCa patients have entered the distant stage of metastasis when diagnosed. This paper preliminarily discusses the clinical prognosis of patients with metastatic prostate cancer undergoing tumor-reducing surgery based on domestic and foreign studies.
%K 转移性前列腺癌，减瘤手术，减瘤性前列腺根治性切除术<br>Metastatic Prostate Cancer
%K Cytoreductive Surgery
%K Cytoreductive Radical Prostatectomy
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=62452